REFERENCES
Strober W, James SP: The immunologic basis of inflammatory bowel disease. J Clin Immunol 6:415–432, 1986
Macdonald TT, Murch SH: Aetiology and pathogenesis of chronic inflammatory bowel disease. Ballieres Clin Gastroenterol 8:1–34, 1994
Larusso NF, Wiesner RH, Ludwig J, MacCarty RL: Primary sclerosing cholangitis. N Engl J Med 310:899–903, 1984
Shaked A, Colonna JO, Goldstein A, Busuttil RW: The interrelation between sclerosing cholangitis and ulcerative colitis in patients undergoing liver transplantation. Ann Surg 215:598–605, 1992
Stephens J, Goldstein R, Crippin J, et al: Effects of orthotopic liver transplantation and immunosuppression on inflammatory bowel disease in primary sclerosing cholangitis patients. Transplant Proc 25:1122–1123, 1993
Riley TR. Schoen RE. Lee RG. Rakela J: A case series of transplant recipients who despite immunosuppression developed inflammatory bowel disease. Am J Gastroenterol 92(2):279–282, 1997
Passfall J, Distler A, Riecken EO, Zeitz M: Development of ulcerative colitis under the immunosuppressive effect of cyclosporine. Clin Invest 70:611–613, 1992
Cuoco L, Tursi A, Cammarota G, Papa A, Fedeli G, Gasbarrini G: Onset of ulcerative colitis during immunosuppressive therapy for liver transplantation. Am J Gastroenterol 92(11):2134–2135, 1997
Lichtenstein GR: Medical therapies for inflammatory bowel disease. Opin Gastroenterol 9:588–599, 1993
Brynskov J, Freund L, Rasmussen SN, Lauritsen K, de Muckadell OS, Williams N, MacDonald AS, Tanton R, Molina F, Campanini MC: A placebo controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Eng J Med 321:845–850, 1989
Demetris AJ, Seaberg EC, Batts KP, Ferrell L, Ludwig J, Markin RS, Belle SH, Detre K: Reliability and predictive value of the NIDDK liver transplant database nomenclature and grading system for cellular rejection of liver allografts. Hepatology 21:408–416, 1995
Knapp AB, Horst DA, Eliopoulos G, Gramm HF, Gaber LW, Falchuk KR, Falchuk ZM, Trey C: Widespread cytomegalovirus gastroenterocolitis in a patient with acquired immunodefi-ciency syndrome. Gastroenterology 85:1399–1402, 1983
Wajsman R, Cappell MS, Biempica L, Cho KC: Terminal ileitis associated with cytomegalovirus and the acquired immunode-ficiency syndrome. Am J Gastroenterol 82:1264–1270, 1987
Sartor RB: Cyclosporine therapy for inflammatory bowel disease. N Engl J Med 330:1897–1898, 1994
Papatheodoridis GV, Hamilton M, Mistry PK, Davidson B, Rolles K: Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut 43(5):639–644, 1998
Bickston SJ. Cominelli F: Treatment of Crohn's disease at the turn of the century. N Engl J Med 339(6):401–402, 1998
Befeler AS, Lissoos TW, Schiano TD, Conjeevaram H, Dasgupta KA, Millis JM, Newell KA, Thisthlethwaite JR, Baker AL: Clinical course and management of inflammatory bowel disease after liver transplantation. Transplantation 15:393–396, 1998
Sandborn WJ, Tremaine WJ: Cyclosporine treatment of inflammatory bowel disease. Mayo Clin Proc 67(10):981–990, 1992
Feagan BG, McDonald JW, Rochon J, Laupacis A, Fedorak KN, Kinnear D, Saibil F, Groll A, Archambault A, Gillies R: Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial. N Engl J Med 330(26):1846–1851, 1994
Sandborn WJ: Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small-bowel and fistulizing Crohn's disease. Am J Gastroenterol 92:876–879, 1997
Fellermann K, Ludwig D, Stahl M, David-Walek T, Strange EF: Steroid-unresponsive acute attacks of inflammatory bowel disease: Immunomodulation by tacrolimus (FK506). Am J Gastroenterol 93:1860–1866, 1998
Lerardi E, Principi M, Francavilla R, Pisani A, Rendina M, Ingrosso M, Guglielmi FW, Panella C, Francavilla A: Oral tracrolimus long-term therapy in patients with Crohn's disease and steroid resistance. Aliment Pharmacol Ther 15:371–377, 2001
Brynskov J, Nielsen OH, Ahnfelt-Ronne I, Bendtzen K: Cytokines and their natural regulation in inflammatory bowel disease: A review. Dig Dis Sci 12:290–304, 1994
Neissner M, Volk BA: Phenotypic and immunoregulatory analysis of intestinal T-cells in patients with inflammatory bowel disease: Evaluation of in-vitro model. Eur J Clin Invest 25:155–164, 1995
Senju M, Hulstaert F, Lowder JR, et al: Flow cytometric analysis of peripheral blood lymphocytes in ulcerative colitis and Crohn's disease. Gut 32:779–783, 1991
Targan S, Hanauer S, van Deventer SJH, et al: A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337:1029–1035, 1997
Neurath MF, Becker C, Barbulescu K: Role of NFκB in immune and inflammatory responses in the gut. Gut 43:856–860, 1998
Kam L, Targan SR: Cytokine-based therapies in inflammatory bowel disease. Curr Opin Gastroenterol 15:302–307, 1999
Hanauer SB: Inflammatory bowel disease. N Engl J Med 334:841–884, 1996
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ramji, A., Owen, D.A., Erb, S.R. et al. CASE REPORT: Post-Liver Transplant Crohn's Disease: Graft Tolerance but Not Self-Tolerance?. Dig Dis Sci 47, 522–527 (2002). https://doi.org/10.1023/A:1017951632444
Issue Date:
DOI: https://doi.org/10.1023/A:1017951632444